Fonte: Journal of Personalized Medicine. Unidade: FOB
Assuntos: OBESIDADE, AGENTES DOPAMINÉRGICOS, MEDICAMENTO
ABNT
BARBOSA, Bárbara Ferraz et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, for obese patients: a systematic review and meta-analysis. Journal of Personalized Medicine, v. 13, 2023Tradução . . Disponível em: https://doi.org/10.3390/jpm13101460. Acesso em: 04 nov. 2024.APA
Barbosa, B. F., Moraes, F. C. A. de, Barbosa, C. B., Santos, P. T. K. P., Silva, I. P. da, Silva, B. A. A. da, et al. (2023). Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, for obese patients: a systematic review and meta-analysis. Journal of Personalized Medicine, 13. doi:10.3390/jpm13101460NLM
Barbosa BF, Moraes FCA de, Barbosa CB, Santos PTKP, Silva IP da, Silva BAA da, Barros JCM, Burbano RMR, Santos NPC dos, Fernandes MR. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, for obese patients: a systematic review and meta-analysis [Internet]. Journal of Personalized Medicine. 2023 ; 13[citado 2024 nov. 04 ] Available from: https://doi.org/10.3390/jpm13101460Vancouver
Barbosa BF, Moraes FCA de, Barbosa CB, Santos PTKP, Silva IP da, Silva BAA da, Barros JCM, Burbano RMR, Santos NPC dos, Fernandes MR. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, for obese patients: a systematic review and meta-analysis [Internet]. Journal of Personalized Medicine. 2023 ; 13[citado 2024 nov. 04 ] Available from: https://doi.org/10.3390/jpm13101460